secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001437749-26-012303
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva targets brilaroxazine patent extension to 2046, plans API switch in RECOVER-2 trial
--------------------------------------------------------------------------------

- Filed composition of matter patent on new brilaroxazine form; pursuing accelerated review to extend exclusivity potentially through 2046.
- Preparing to seek FDA alignment to switch API and formulation in RECOVER-2; feedback expected mid-2026.
- RECOVER-2 trial activities start Q2 2026, patient enrollment Q3 2026, completion expected Q4 2027.
- Closed $10M financing on March 20, 2026; pro forma cash ~$23M, expected to fund operations into Q1 2027.
- Evaluating strategic alternatives to maximize brilaroxazine value; recent reverse stock split and financing were difficult but necessary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/0001437749-26-012303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/rvph20260414_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-012303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer